Biography:

After graduating in medicine from Cambridge University, he trained in respiratory medicine and clinical pharmacology in Manchester. This included experience of phase 1 & 2 studies, and training in immunopharmacology. After gaining an MD from the University of Manchester, he took up a post in respiratory pharmacology based in the University Hospital of South Manchester.  His research interests are the pharmacotherapy of asthma and COPD with studies spanning from basic pharmacology investigations of anti-inflammatory drug action to clinical trials. 

Present Appointment:    Reader in Clinical Pharmacology & Respiratory Medicine
1st August 2009 to present date   Respiratory Research Group, School of Translational Medicine,
                                              University of Manchester
                                             Honorary Medical Director Medicines Evaluation Unit
                                             Honorary Consultant Respiratory Physician UHSMFT
Previous Appointments:
06/03 – 07/09                      Senior Lecturer in Clinical Pharmacology & Respiratory Medicine
03/97 – 03/03                      Senior Registrar Chest Medicine & Clinical Pharmacology
08/96 – 02/97                      Locum Registrar Chest Medicine
08/94 – 07/96                       Senior House Officer General Medicine (2 year rotation scheme)
08/92 – 07/92                        House Officer

Supervision of Postgraduate Students
Thesis Awarded: 8
Students currently registered: 7 of which 2 co-supervised

Recent grants
Principal applicant
2004-2007         BBSRC Case PhD studentship £21,000
2008-2009         Chiesi project grant: Corticosteriod resistance in COPD £60,000
2008-2010         FP7 European Union grant: Emphysema Vs small airway disease    £213,190
2008-2010         NWLC Charity grant: Corticosteriod Insensitivity in Asthma   £117,715
2009-2010         GSK Project Grant: Phenotyping of small airway disease in COPD   £50,000
2009-2010         BBSRC/GSK PhD Case Award    £67,613
2009-2010         Chiesi project grant: PDE4 Inhibitors in COPD £44,000
2009-2010         UCB grant: Role of IL-17 in COPD and moderate to severe asthma   £99,992
2009-2011         GSK Project Grant: Primary Cell Pharmacology Studies In Asthma & COPD   £192,000
2009-2011         Chiesi project grant: Small airway disease in COPD  £35,000
2007-2010        MRC clinical training fellowship  £210,000                           
                                                                              
Publications
63 papers. Selected recent papers shown below

• Singh SD, Richards D, Knowles RG, Schwartz S, Woodcock AA, Langley SJ, O’Connor BJ. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma.  Am J Respir Crit Care Med 2007:176; 988-93
• Singh SD, Brooks J, Hagan G, Cahn A, O'Connor B. ‘Triple’ therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63:592-8.
• Kirkham S, Kolsum U, Rousseau K, Singh SD, Vestbo J, Thornton DJ.   MUC5B is the Major Mucin in the Gel-phase of Sputum in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2008;178:1033-9.
• Kent L, Smyth L, Plumb J, Clayton C, Fox S, Ray D, Farrow S, Singh SD.  Inhibition of LPS stimulated COPD macrophage inflammatory gene expression by Dexamethasone and the p38 MAPK inhibitor SB706504. J Pharmacol Exp Ther. 2009;328:458-68
• Gibbs JE, Beesley S, Plumb J, Singh SD, Farrow S, Ray DW, Loudon AS.  Circadian timing in the lung; a specific role for bronchiolar epithelial cells.  Endocrinology. 2009; 150:268-76
• Plumb J, Smyth LJC, Adams HR, Vestbo J, Bentley A, Singh SD. Increased T regulatory cells within lymphocyte follicles in moderate COPD.  Eur Respir J  2009; 34:89-94
• Roy K, Smith J, Kolsum U, Borrill Z, Vestbo J, Singh D. COPD phenotype description using principal components analysis. Respir Res 2009; 29:10:41
• Kane B, Kolsum U, Southworth T, Armstrong J, Woodcock A, Singh D. The effects of smoking on the LPS  response and glucocorticoid sensitivity of alveolar macrophages of patients with asthma. Chest. 2009;136:163-70. 
• Al-shair K, Kolsum U, Berry P, Smith J, Caress A, Singh D, Vestbo J. Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale. Thorax. 2009;64:950-5
• Singh D, Petavy F, Macdonald AJ, Lazaar AL, O’Connor BJ. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma Respir Res. 2010;11:26
• Nicholas B, Howarth P, Guha-Nyogi B, Singh D, Djukanovic R. Identification of Lipocalin and Apolipoprotein A1 as Biomarkers of Chronic Obstructive Pulmonary Disease.  Am J Respir Crit Care Med. 2010 15;181:1049-60
• Berry A, Plumb J, Farrow S, Singh D, Ray D Donn R. Interferon inducible factor 16 (IFI16) is a novel modulator of glucocorticoid action. FASEB 2010 24;1700-13
• Singh D, Edwards L, Tal-Singer R, Rennard S. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res. 2010;11:77
• Smyth LJ, Eustace A, Kolsum U, Blaikely J, Singh D. Increased airway T regulatory cells in asthmatic subjects. Chest. 2010 May 7. [Epub ahead of print]

Atrás